Pharmaceutical

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).

Jun 1, 2025 - 06:00
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

Astellas and Evopoint sign ADC licensing deal

Next Article

FDA Halts Rocket Pharmaceuticals’ Gene Therapy Trial After Patient Death

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BioNTech and DualityBio team up to develop ADC therapeutics for cancer

BioNTech and DualityBio team up to develop ADC therapeu...

Apr 3, 2023

US FDA approves Kamada’s application to manufacture Cytogam

US FDA approves Kamada’s application to manufacture Cyt...

May 4, 2023

Avenge Bio secures FDA orphan drug designation for mesothelioma therapy

Avenge Bio secures FDA orphan drug designation for meso...

Jun 17, 2023